AbbVie is investing $195m to strengthen domestic active pharmaceutical ingredient (API) production within the US, with the ...

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

This episode of Pharma Pulse explores AbbVie’s $195 million investment to expand US API production, new survey results ...

AbbVie will invest $195M to expand API manufacturing at its North Chicago plant, boosting U.S. pharmaceutical innovation, ...

AbbVie (ABBV) announced a $195M investment in its North Chicago, Illinois manufacturing plant to expand domestic active ...

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and ...

AbbVie (ABBV) announced a $195 million investment in its North Chicago manufacturing facility to boost domestic API ...

The global biopharma firm will build a new API production facility near its global headquarters in North Chicago.

As pharma companies big and small play up their U.S. investment plans during the second Trump administration, the particulars ...

AbbVie (NYSE: ABBV) today announced a $195 million investment in its North Chicago, Illinois manufacturing plant to expand domestic active pharmaceutical ingredient (API) production in the U.S. This ...

AbbVie will invest $195 million in its North Chicago, Illinois, manufacturing plant to expand domestic API production in the ...

The company’s commitment to its North Chicago, Ill. plant is part of a previously announced $10 billion capital investment ...